Clinical Evidence


Unprecedented clinical results for the most challenging patients

PROMISE I U.S. Early Feasibility Study Data

Amputation Free Survival at 6 months
Wounds Healed or Healing at 6 Months
Results of the LimFlow System in the PROMISE I Trial (at 6 months). Presented at Vascular Interventional Advances Conference (VIVA), November 2019, Daniel Clair, MD.

LimFlow Clinical Program

150+ Patients Target

 First-in-HumanPROMISE IALPS RegistryPROMISE InternationalPROMISE II U.S. Pivotal
# Centers1742020
# Patients7323250+60-120 (adaptive)
Primary EndpointMajor adverse limb and coronary eventsAFS at 6 monthsAFS at 6 monthsAFS at 6 monthsAFS at 6 months
ProtocolSingle-center, prospective, single-armMulti-center, prospective, single-armMulti-center, retrospectiveMulti-center, prospective, single-armMulti-center, prospective, efficacy and safety study
CountriesSingaporeU.S.Alkmaar, Leipzig, Paris, SingaporeUnited Kingdom, Europe, Singapore U.S., Japan
Secondary EndpointsAFS, wound healing, perfusionWound healing, patency, perfusionWound healing, patency, perfusionWound healing, patency, perfusion Wound healing, patency, perfusion
Total Length of Follow-up1 year2 years2 years1 year3 years

LimFlow, Inc.
2934 Scott Boulevard
Santa Clara, CA 95054 USA
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use.
©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.